{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T16:34:24Z","timestamp":1792946064362,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.conctc.2026.101694","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:41:49Z","timestamp":1790689309000},"page":"101694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Stakeholder-reported perspectives on decentralized clinical trials: A multi-country descriptive survey"],"prefix":"10.1016","volume":"54","author":[{"given":"Arghya","family":"Biswas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2026.101694_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cpt.1441","article-title":"Decentralized trials in the age of real-world evidence and inclusivity in clinical investigations","volume":"106","author":"Khozin","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.conctc.2026.101694_bib3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cct.2014.04.009","article-title":"Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial","volume":"38","author":"Orri","year":"2014","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.conctc.2026.101694_bib4","series-title":"Conducting Clinical Trials with Decentralized Elements","year":"2024"},{"key":"10.1016\/j.conctc.2026.101694_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s43441-022-00454-5","article-title":"Assessing the financial value of decentralized clinical trials","volume":"57","author":"DiMasi","year":"2023","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.conctc.2026.101694_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70117","article-title":"Decentralized clinical trials in the era of real-world evidence: a statistical perspective","volume":"18","author":"Chen","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.conctc.2026.101694_bib7","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2119097118","article-title":"Core concept: in the wake of COVID-19, decentralized clinical trials move to center stage","volume":"118","author":"Banks","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"10.1016\/j.conctc.2026.101694_bib8","article-title":"The impact of COVID-19 on the clinical trial","volume":"16","author":"Chen","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.conctc.2026.101694_bib10","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1186\/s13063-022-06706-x","article-title":"A cross-sectional survey on the early impact of COVID-19 on the uptake of decentralised trial methods in the conduct of clinical trials","volume":"23","author":"Suman","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.conctc.2026.101694_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1081150","article-title":"Decentralized clinical trials (DCTs): a few ethical considerations","volume":"10","author":"Petrini","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.conctc.2026.101694_bib12","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.mayocp.2022.10.001","article-title":"The digitization and decentralization of clinical trials","volume":"98","author":"Harmon","year":"2023","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.conctc.2026.101694_bib13","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1016\/S2589-7500(23)00052-3","article-title":"Decentralised clinical trials: ethical opportunities and challenges","volume":"5","author":"Vayena","year":"2023","journal-title":"Lancet Digit. Health"},{"key":"10.1016\/j.conctc.2026.101694_bib14","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2024.28047","article-title":"Manual vs AI-Assisted prescreening for trial eligibility using large language models\u2014A randomized clinical trial","volume":"333","author":"Unlu","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.conctc.2026.101694_bib15","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s43441-019-00006-4","article-title":"Legal, regulatory, and practical issues to consider when adopting decentralized clinical trials: recommendations from the clinical trials transformation initiative","volume":"54","author":"Apostolaros","year":"2020","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.conctc.2026.101694_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.12793\/tcp.2024.32.e2","article-title":"The landscape of decentralized clinical trials (DCTs): focusing on the FDA and EMA guidance","volume":"32","author":"Park","year":"2024","journal-title":"Transl. Clin. Pharmacol."},{"key":"10.1016\/j.conctc.2026.101694_bib21","article-title":"Exploring implementation challenges of decentralized clinical trials: a qualitative study of policy stakeholder perspectives in Denmark","volume":"11","author":"Hestbjerg","year":"2025","journal-title":"Digit. Health"},{"key":"10.1016\/j.conctc.2026.101694_bib22","article-title":"Decentralized clinical trials: a comprehensive analysis of trends, technologies, and global challenges, PLOS digit","volume":"5","author":"Kijewski","year":"2026","journal-title":"Health"},{"key":"10.1016\/j.conctc.2026.101694_bib23","first-page":"91","article-title":"Decentralized clinical trials: potential for equity in digital health","volume":"304","author":"Weber","year":"2023","journal-title":"Stud. Health. Technol. Inform."},{"key":"10.1016\/j.conctc.2026.101694_bib24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cpt.2628","article-title":"Opportunities and challenges for decentralized clinical trials: european regulator's perspective","volume":"112","author":"de Jong","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.conctc.2026.101694_bib25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1186\/s13063-022-06521-4","article-title":"A secondary qualitative analysis of stakeholder views about participant recruitment, retention, and adherence in decentralised clinical trials (DCTs)","volume":"23","author":"Coyle","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.conctc.2026.101694_bib28","article-title":"Comparison of participant and site perceptions of decentralized clinical trials in the USA, Mayo clin","volume":"3","author":"Barge","year":"2025","journal-title":"PLOS Digit. Health"},{"key":"10.1016\/j.conctc.2026.101694_bib30","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1016\/S2214-109X(24)00521-7","article-title":"Better engagement, better evidence: working in partnership with patients, the public, and communities in clinical trials with involvement and good participatory practice","volume":"13","author":"Gobat","year":"2025","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.conctc.2026.101694_bib31","doi-asserted-by":"crossref","DOI":"10.2196\/26813","article-title":"Stakeholder perspectives on barriers and facilitators for the adoption of virtual clinical trials: qualitative study","volume":"23","author":"Coert","year":"2021","journal-title":"J. Med. Internet Res."},{"key":"10.1016\/j.conctc.2026.101694_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4103\/picr.picr_219_22","article-title":"The role of remote data capture, wearables, and digital biomarkers in decentralized clinical trials","volume":"15","author":"Chodankar","year":"2024","journal-title":"Perspect. Clin. Res."},{"key":"10.1016\/j.conctc.2026.101694_bib33","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.conctc.2018.06.008","article-title":"Building clinical trials around patients: evaluation and comparison of decentralized and conventional site models in patients with low back pain","volume":"11","author":"Sommer","year":"2018","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.conctc.2026.101694_bib34","author":"Redeker"},{"key":"10.1016\/j.conctc.2026.101694_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cardfail.2023.04.001","article-title":"Recruitment strategies of a decentralized randomized placebo controlled clinical trial: the canagliflozin impact on health status, quality of life and functional status in heart failure (CHIEF-HF) trial","volume":"29","author":"Nassif","year":"2023","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.conctc.2026.101694_bib36","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cpt.70070","article-title":"Operationalizing decentralized clinical trials: technology insights from the Trials@Home RADIAL proof-of-concept trial","volume":"118","author":"Hanke","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.conctc.2026.101694_bib37","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/cpt.70075","article-title":"Selecting and preparing clinical sites for the successful conduct of decentralized clinical trial activities-findings from the Trials@Home RADIAL proof-of-concept trial","volume":"118","author":"Lipinska","year":"2025","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865426001018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865426001018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T15:49:37Z","timestamp":1792943377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865426001018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":28,"alternative-id":["S2451865426001018"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2026.101694","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stakeholder-reported perspectives on decentralized clinical trials: A multi-country descriptive survey","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2026.101694","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101694"}}